Cellular Engineering Technologies
Cellular Engineering Technologies is a privately held, micro-scale biopharmaceutical company founded in 2000 in Coralville, Iowa, focused on drug discovery to develop patient therapies. Its current operating activity is not verifiable from public sources.
- Company typePrivate
- Founded2000
- HeadquartersCoralville, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Cellular Engineering Technologies firmographics
Firmographics- Name
- Cellular Engineering Technologies
- Website
- https://celleng-tech.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Unknown
- Headcount range
- 1–10 employees
- Short description
- Cellular Engineering Technologies is a privately held, micro-scale biopharmaceutical company founded in 2000 in Coralville, Iowa, focused on drug discovery to develop patient therapies. Its current operating activity is not verifiable from public sources.
- Ownership category
- akta.pro rank
Cellular Engineering Technologies industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
Keywords
Where Cellular Engineering Technologies is headquartered
LocationHeadquarters
- HQ city
- Coralville
- HQ country
- United States
- HQ region
- North America
Markets served
Cellular Engineering Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Cellular Engineering Technologies product offering
Product offeringCore offering
Cellular Engineering Technologies (CET) is a biopharmaceutical company focused on transforming patient therapy through drug discovery. The company works on developing cell-based therapeutic products, with activity referenced in the placental stem cell therapy market. The firm operates with a small team (1-10 employees) and its primary website domain has expired, indicating limited or no active web presence.
Differentiator
Problem solved
Functional benefit
Cellular Engineering Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cellular Engineering Technologies competitors and assessment
Company assessmentDirect peers
- Athersys: Athersys developed MultiStem, an off-the-shelf cell therapy platform for regenerative medicine indications. It is a directly comparable cell therapy peer operating in adjacent indications with a similar early-clinical-stage posture.
- Mesoblast: Mesoblast is a clinical-stage cell therapy developer focused on mesenchymal lineage cell therapies for inflammatory and immune-mediated diseases. It is a directly comparable allogeneic cell therapy peer, though significantly more advanced and capitalized than CET.
- Capricor Therapeutics: Capricor develops cell-derived exosome and cell therapy products (CAP-1002) for Duchenne muscular dystrophy and other indications. It is a directly comparable small-cap cell therapy developer at a similar stage of development.
- BrainStorm Cell Therapeutics: BrainStorm develops autologous cell therapies (NurOwn) for neurodegenerative diseases. It is a directly comparable small-cap cell therapy developer with similar headcount and capital constraints relative to larger biopharma.
- Pluristem Therapeutics: Pluristem develops placenta-derived (placental) cell therapies, directly paralleling the placental stem cell therapy category referenced for CET. Both are small-cap cell therapy developers leveraging placenta-derived cellular platforms, making Pluristem the closest functional analog.
- International Stem Cell Corporation: ISCO developed parthenogenetic stem cell-based therapies, providing a directly comparable small-cap stem cell therapy peer focused on novel cell engineering approaches analogous to CET's cellular engineering positioning.
Emerging players
- VistaGen Therapeutics: VistaGen is a small clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies. It overlaps with CET's positioning as a small, multi-asset biopharmaceutical developer.
Market position
Customer concentration
Cellular Engineering Technologies social profiles
Digital presenceCellular Engineering Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellular Engineering Technologies leadership team
Management profileNumber of profiles
Cellular Engineering Technologies funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellular Engineering Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellular Engineering Technologies
What does Cellular Engineering Technologies do?
Cellular Engineering Technologies (CET) is a biopharmaceutical company focused on transforming patient therapy through drug discovery. The company works on developing cell-based therapeutic products, with activity referenced in the placental stem cell therapy market. The firm operates with a small team (1-10 employees) and its primary website domain has expired, indicating limited or no active web presence.
When was Cellular Engineering Technologies founded?
Cellular Engineering Technologies was founded in 2000. It employs 1 to 10 people.
Where is Cellular Engineering Technologies based?
Cellular Engineering Technologies is headquartered in Coralville, United States, in the North America region.
Who are Cellular Engineering Technologies's main competitors?
Direct peers on record are Athersys, Mesoblast, Capricor Therapeutics, BrainStorm Cell Therapeutics, Pluristem Therapeutics and International Stem Cell Corporation. VistaGen Therapeutics is listed as an emerging player.
Does Cellular Engineering Technologies have an API?
No public API is recorded for Cellular Engineering Technologies.
What industry is Cellular Engineering Technologies in?
Cellular Engineering Technologies's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 541714 and its SIC code is 2836.